The soluble epoxide hydrolase (sEH) in mammalian systems is a member of the α/β-hydrolase fold family of enzymes and it shows a high degree of selectivity for epoxides of fatty acids.The epoxides of arachidonic acid or epoxyeicosatrienoic acids (EET) are particularly good substrates.These EET appear to be major components of the endothelium-derived hyperpolarizing factors (EDHF).As such, EET cause vasodilation and reduce blood pressure.The EET also have variable biological effects, such as anti-inflammatory, fibrinolysis, stimulating angiogenesis, etc.Whereas inhibitors of the regulatory enzyme—soluble epoxide hydrolase inhibitors (sEHi), can increase the level of EET and mimic those effects.Therefore, sEH inhibitors are being extensively studied as a therapeutic potential for the treatment of hypertension, atherosclerosis, and inflammatory diseases.